佐力藥業(300181.SZ):爭取未來把烏靈系列打造成10個產品的大家庭
格隆匯2月1日丨佐力藥業(300181.SZ)於近期接受投資者調研,就“公司烏靈系列其他產品的開發進度如何?”,公司回覆稱,公司現在已擁有烏靈膠囊、靈澤片、靈蓮花顆粒3個烏靈系列獨家產品,加上公司目前在研創新藥靈香片,也是以烏靈菌粉入藥,按現代中醫理論指導組方治療現代疾病的中藥製劑,屬於中藥一類創新藥,目前已經完成臨牀前研究,未來公司也會繼續圍繞以烏靈菌粉為原料並依據名醫處方開發獨家烏靈系列新產品。同時,公司目前請了國家級名中醫在進行二個產品組方,爭取未來把烏靈系列打造成10個產品的大家庭。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.